INT10976

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1988
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 13
Total Number 13
Disease Relevance 5.11
Pain Relevance 1.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (ENPP3)
Anatomy Link Frequency
vasculatures 1
ENPP3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Restless leg syndrome 10 99.78 Very High Very High Very High
adenocard 15 99.08 Very High Very High Very High
anesthesia 8 94.44 High High
ketamine 1 89.20 High High
isoflurane 2 88.00 High High
Pain 2 84.40 Quite High
qutenza 17 77.52 Quite High
lidocaine 7 76.00 Quite High
ischemia 4 51.52 Quite High
Dopamine 3 36.88 Quite Low
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 45 99.78 Very High Very High Very High
Atherosclerosis 10 95.80 Very High Very High Very High
Asthma 15 95.68 Very High Very High Very High
Dilated Cardiomyopathy 5 95.24 Very High Very High Very High
Chronic Obstructive Pulmonary Disease 1 95.20 Very High Very High Very High
Adult Respiratory Distress Syndrome 24 95.12 Very High Very High Very High
Heart Rate Under Development 11 92.16 High High
Peripheral Arterial Disease 4 88.88 High High
Polycystic Kidney Disease 1 88.64 High High
Acute Decompensated Heart Failure (ADHF) 1 87.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In order to regulate myocardial contractility and after-load, use of a phosphodiesterase III inhibitor was considered, although phosphodiesterase III inhibitors are known to induce arrhythmias, which should be avoided in dilated cardiomyopathy patients.
Negative_regulation (inhibitor) of phosphodiesterase III associated with dilated cardiomyopathy
1) Confidence 0.42 Published 1998 Journal Masui Section Abstract Doc Link 9513340 Disease Relevance 0.39 Pain Relevance 0.23
OBJECTIVE: Enoximone is a phosphodiesterase III inhibitor frequently used to improve cardiac output (CO) in man.
Negative_regulation (inhibitor) of phosphodiesterase III
2) Confidence 0.40 Published 2007 Journal Vet Anaesth Analg Section Abstract Doc Link 17696974 Disease Relevance 0 Pain Relevance 0.08
This action is most likely due to inhibition of phosphodiesterase-III, as has been suggested for many other cardiotonic agents.
Negative_regulation (inhibition) of phosphodiesterase-III
3) Confidence 0.40 Published 1988 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 2851676 Disease Relevance 0.14 Pain Relevance 0
Clinical use of amrinone (a selective phosphodiesterase III inhibitor) in reconstructive surgery.
Negative_regulation (inhibitor) of phosphodiesterase III
4) Confidence 0.29 Published 2001 Journal Plast. Reconstr. Surg. Section Title Doc Link 11743379 Disease Relevance 0.23 Pain Relevance 0.12
Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown.
Negative_regulation (inhibitor) of phosphodiesterase III associated with adenocard
5) Confidence 0.29 Published 2001 Journal Plast. Reconstr. Surg. Section Abstract Doc Link 11743379 Disease Relevance 0.16 Pain Relevance 0.11
It has been previously shown that cilostazol (Pletal), a drug for relief of symptoms of intermittent claudication, potently inhibits cyclic nucleotide phosphodiesterase type 3 (PDE3) and moderately inhibits adenosine uptake.
Negative_regulation (inhibits) of phosphodiesterase type 3 associated with adenocard and restless leg syndrome
6) Confidence 0.22 Published 2004 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 15243309 Disease Relevance 0.18 Pain Relevance 0.30
We have demonstrated that a phosphodiesterase 3 inhibitor, cilostazol, reduces bronchial hyperresponsiveness to inhaled methacholine in elderly patients with stable asthma [10].
Negative_regulation (inhibitor) of phosphodiesterase 3 associated with asthma
7) Confidence 0.09 Published 2005 Journal Cough Section Body Doc Link PMC1336741 Disease Relevance 0.75 Pain Relevance 0.12
Milrinone is a selective phosphodiesterase-3 inhibitor with significant inotropic and vasodilatory effects for both pulmonary and systemic vasculatures.
Negative_regulation (inhibitor) of phosphodiesterase-3 in vasculatures
8) Confidence 0.03 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605326 Disease Relevance 0.72 Pain Relevance 0
Cilostazol was developed as a selective inhibitor of cyclic nucleotide phosphodiesterase 3 (PDE3).
Negative_regulation (inhibitor) of phosphodiesterase 3
9) Confidence 0.03 Published 2006 Journal Curr. Pharm. Des. Section Abstract Doc Link 16472148 Disease Relevance 0.34 Pain Relevance 0.11
R 80122 is a newly synthesized, selective phosphodiesterase III inhibitor.
Negative_regulation (inhibitor) of phosphodiesterase III
10) Confidence 0.02 Published 1992 Journal Arch Int Pharmacodyn Ther Section Abstract Doc Link 1530374 Disease Relevance 0 Pain Relevance 0
Cilostazol, a selective phosphodiesterase III inhibitor with vasodilator, antiplatelet, and antiproliferative properties, has recently been approved for the treatment of IC symptoms in the United States.
Negative_regulation (inhibitor) of phosphodiesterase III associated with restless leg syndrome
11) Confidence 0.01 Published 2002 Journal J Clin Pharmacol Section Abstract Doc Link 12463722 Disease Relevance 1.17 Pain Relevance 0.58
Cilostazol, a selective phosphodiesterase type III inhibitor, has vasodilatory, antiplatelet, and antithrombotic actions, as well as being the first-choice drug for the intermittent claudication due to peripheral vascular disease.
Negative_regulation (inhibitor) of phosphodiesterase type III associated with restless leg syndrome and increased venous pressure under development
12) Confidence 0.01 Published 2007 Journal Arq Bras Endocrinol Metabol Section Abstract Doc Link 18209897 Disease Relevance 0.68 Pain Relevance 0.17
Cilostazol, a drug commonly used in the treatment of intermittent claudication is a selective phosphodiesterase III inhibitor.
Negative_regulation (inhibitor) of phosphodiesterase III associated with restless leg syndrome
13) Confidence 0.00 Published 2009 Journal Eur. J. Pharmacol. Section Abstract Doc Link 19545562 Disease Relevance 0.34 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox